Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid arthritis: results from the treatment of early aggressive rheumatoid arthritis trial.

MLA

Aslibekyan, S., et al. “Genetic Variants Associated with Methotrexate Efficacy and Toxicity in Early Rheumatoid Arthritis: Results from the Treatment of Early Aggressive Rheumatoid Arthritis Trial.” The Pharmacogenomics Journal, vol. 14, no. 1, Feb. 2014, pp. 48–53. EBSCOhost, https://doi.org/10.1038/tpj.2013.11.

APA

Aslibekyan, S., Brown, E. E., Reynolds, R. J., Redden, D. T., Morgan, S., Baggott, J. E., Sha, J., Moreland, L. W., O’Dell, J. R., Curtis, J. R., Mikuls, T. R., Bridges, S. L., Jr, & Arnett, D. K. (2014). Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid arthritis: results from the treatment of early aggressive rheumatoid arthritis trial. The Pharmacogenomics Journal, 14(1), 48–53. https://doi.org/10.1038/tpj.2013.11

Chicago

Aslibekyan, S, E E Brown, R J Reynolds, D T Redden, S Morgan, J E Baggott, J Sha, et al. 2014. “Genetic Variants Associated with Methotrexate Efficacy and Toxicity in Early Rheumatoid Arthritis: Results from the Treatment of Early Aggressive Rheumatoid Arthritis Trial.” The Pharmacogenomics Journal 14 (1): 48–53. doi:10.1038/tpj.2013.11.